Vanoxerine: cellular mechanism of a new antiarrhythmic - Wikidata - wikimedia - TriplyDB

Vanoxerine: cellular mechanism of a new antiarrhythmic

Vanoxerine: cellular mechanism of a new antiarrhythmic

http://www.wikidata.org/entity/Q24626475

about

Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results Electromechanical and atrial and ventricular antiarrhythmic actions of CIJ-3-2F, a novel benzyl-furoquinoline vasodilator in rat heart.Slow delayed rectifying potassium current (IKs ) - analysis of the in vitro inhibition data and predictive model development.Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.MICE models: superior to the HERG model in predicting Torsade de Pointes.Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation.

P2860

Q24595819-3B78A1A2-94D3-4A81-8CC4-E7ADD799DC78 Q34025122-712D96FC-FD6E-46B4-B3A5-F659DC37A86F Q34159048-BC99032B-D218-4A75-9149-0F7A31970A02 Q36329486-4A3E57C9-DD06-45A7-BDF4-6679952F8116 Q36968169-0C5C87C1-8C4B-4584-8B71-A870F948B053 Q38837020-0E9C4B26-95C3-4F6A-88AE-77D9DF8AAA68 Q38853630-41AF6072-10BC-4984-8A02-1BA5A925DCF9

P2860

Vanoxerine: cellular mechanism of a new antiarrhythmic

http://www.wikidata.org/entity/Q24626475

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Vanoxerine: cellular mechanism of a new antiarrhythmic

@ast

Vanoxerine: cellular mechanism of a new antiarrhythmic

@en

Vanoxerine: cellular mechanism of a new antiarrhythmic

@nl

type

label

Vanoxerine: cellular mechanism of a new antiarrhythmic

@ast

Vanoxerine: cellular mechanism of a new antiarrhythmic

@en

Vanoxerine: cellular mechanism of a new antiarrhythmic

@nl

prefLabel

Vanoxerine: cellular mechanism of a new antiarrhythmic

@ast

Vanoxerine: cellular mechanism of a new antiarrhythmic

@en

Vanoxerine: cellular mechanism of a new antiarrhythmic

@nl

P1433

Q24626475-DEB036B7-C3CC-46B3-B854-221D5EA8E573

P1476

Q24626475-39191552-D823-47B1-9197-D49A65CC01DE

P2093

Q24626475-2C46F14A-E17B-4718-BA67-EE64C29C8E60

Q24626475-C0B53971-2EA0-4A21-9345-DCA39A328C9A

Q24626475-E7AF12E5-16FA-4702-9EB6-016FBD20ACA3

Q24626475-EBE0E8F2-5C01-464D-B2A3-1B9EE79CA68E

Q24626475-F7A4EAFD-CD1E-4FB1-ABEB-D6B383F0FD21

P2860

Q24626475-080A88F9-04C6-4C8F-A306-DABACA405B74

Q24626475-0A9E315C-D20B-4283-8920-61F2A437ED61

Q24626475-0F8DBBF5-C996-4ADF-B4A1-5722C7A5D8EF

Q24626475-25C65273-7383-4F58-98BA-E262B9994B42

Q24626475-25CE62B4-DF2C-4ED6-9BE2-37A3714DF46B

Q24626475-3558C466-121C-42C6-86BC-7AE25532E57C

Q24626475-440F9E7D-258B-47E1-9ACF-F8CAAAB97E22

Q24626475-51AC8FFE-E016-4B81-AE9E-E243E0BC9892

Q24626475-54CC028E-6A0E-4CDA-97BF-B0D23B5E27F4

Q24626475-5FA70380-5FFA-42E6-ACF0-7B7DEDDB0A74

P304

Q24626475-0A9A586F-67D8-4FAE-B738-00B461A55820

P31

Q24626475-CF74617B-5635-4C89-95C8-4F544D4F4AE5

P356

Q24626475-E826D1AE-5732-4281-B63A-6E514EEE435F

P407

Q24626475-2987F158-D8F9-4FDC-958E-AA7BE9A33762

P433

Q24626475-638CB9E3-583C-48B8-8B07-3B9F4D1E155F

P478

Q24626475-D7E1FCF1-67BC-4DF4-85FD-821FEDAE0CD7

P577

Q24626475-34E0538B-23AD-4CD2-B4D1-577A2951A614

P5875

Q24626475-1BC8FAD9-CE98-4F9B-90AE-AFCC30A0FBB9

P698

Q24626475-20A8EA04-0071-4C53-9898-902AF73ACA7B

P932

Q24626475-F59F9319-8FC2-44D7-97CF-CB461A28FC46

P356

J.1540-8167.2009.01623.X

P1433

Journal of Cardiovascular Electrophysiology

P1476

Vanoxerine: cellular mechanism of a new antiarrhythmic

@en

P2093

Albert L Waldo

http://www.w3.org/2001/XMLSchema#string

Antonio E Lacerda

http://www.w3.org/2001/XMLSchema#string

Arthur M Brown

http://www.w3.org/2001/XMLSchema#string

Gan-Xin Yan

http://www.w3.org/2001/XMLSchema#string

Yuri A Kuryshev

http://www.w3.org/2001/XMLSchema#string

P2860

KChAP/Kvbeta1.2 interactions and their effects on cardiac Kv channel expression

Vanoxerine National Institute on Drug Abuse

Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes

A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects

Vanoxerine, a new drug for terminating atrial fibrillation and flutter

Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels.

Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter.

Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations.

Dronedarone: a new treatment for atrial fibrillation.

A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need.

P304

301-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1540-8167.2009.01623.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26883702

http://www.w3.org/2001/XMLSchema#string

P698

19817928

http://www.w3.org/2001/XMLSchema#string

P932

3107714

http://www.w3.org/2001/XMLSchema#string